N-Desmethyl imatinib D8 is octa-deuterated form of N-Desmethyl imatinib, which is an N-demethylated metabolite of Imatinib
(gleevec). Imatinib is a BCR-ABL inhibitor approved for treating chronic
myelogenous leukemia (CML) and certain forms of acute lymphoblastic
leukemia (ALL).